The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Konstance NicolopoulosMagdalena Ruth MoshiDanielle StringerNing MaMathias JenalThomas VreugdenburgPublished in: Archives of osteoporosis (2023)
In MPC on HAT, denosumab (relative to placebo) was effective at preventing vertebral fractures and improving BMD at the FN and LS. Moreover, in WBC on AAIT, denosumab (relative to placebo) improved BMD at the FN, LS, TH, and TRO, as well as prevent vertebral fracture.
Keyphrases
- bone mineral density
- estrogen receptor
- postmenopausal women
- body composition
- double blind
- giant cell
- phase iii
- randomized controlled trial
- papillary thyroid
- placebo controlled
- small molecule
- systematic review
- clinical trial
- squamous cell carcinoma
- squamous cell
- open label
- mesenchymal stem cells
- lymph node metastasis
- cell therapy
- replacement therapy